Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
ANI PHARMACEUTICALS INC
Bear Case (25th pct.)
6.4% vs price
Base Case (Median)
43.1% vs price
Bull Case (75th pct.)
88.4% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $165.23 | 128.9% | High (40%) |
| PE Comparable | $103.29 | 43.1% | Medium (25%) |
| Growth Trajectory DCF | $110.06 | 52.5% | Medium (20%) |
| Graham Number | $51.43 | -28.7% | Medium (40%) |
| EV/EBITDA | $102.23 | 41.6% | Medium (20%) |
| EV/FCF | $161.88 | 124.3% | Medium (20%) |
| Earnings Power Value | $25.07 | -65.3% | Medium (50%) |
Based on 7 out of 7 methods, ANIP appears undervalued at the current price of $72.18. The base case fair value of $103.29 implies 43.1% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.